Vitae Pharmaceuticals (VTAE) Nearly Doubles As Stock Soars

Vitae Pharmaceuticals (VTAE) Nearly Doubles As Stock Soars

Following a “positive top line results” in a “proof-of-concept clinical trial” revolving around its oral medication used to combat and treat psoriasis, shares in the Fort Washington, Pa.-based Vitae Pharmaceuticals nearly doubled before coming back to Earth later in the day.

Clinical trial a success for Vitae

Presently, treatment for the auto-immune disorders is generally dominated by injectable antibody therapy, but Vitae is hoping that its oral treatment might offer new hope for both stakeholders in the company and sufferers of psoriasis. Psoriasis, is a fairly common condition where skin cells build up to essentially form scales on the skin or in milder cases — dry, itchy patches of skin.

This Hedge Fund Believes The New Real Estate Cycle Is “Well Underway”

REITChilton Capital's REIT Composite was up 6.1% last month, compared to the MSCI U.S. REIT Index, which gained 4.4%. Year to date, Chilton is up 6.3% net and 6.5% gross, compared to the index's 8.8% return. The firm met virtually with almost 40 real estate investment trusts last month and released the highlights of those Read More

The medication, which if approved will certainly get a sexier name than VTP-43742, was recently put through a double-blind, randomized, placebo-controlled trials that the company and analysts are roundly calling a success. In addition to the treatment of psoriasis, the company hopes that it’s pill can help with the treatment of other auto-immune disorders. However, the trial concentrated on psoriasis patients. The participants received multiple doses over a four-week trial according to the company.

Those that received dosages of 350 milligrams showed a 24% reduction of psoriasis compared to the placebo group; while those that received a “double dose” of 700 milligrams showed a 30% reduction in their patches of psoriasis.

Later this year, the company is planning a 16-week clinical trial in order “to continue to asses the efficacy, safety and tolerability” of the medication, Richard Gregg, the company’s chief scientific officer, said in a statement issued with the announcement.

Stock’s poor year gets a boost in trading today

Late in 2015 (December 29), Vitae shares were trading at $18.31. However, prior to today’s announcement shares had declined 77% in 2016 and closed trading Wednesday at $4.11.

However, following the company’s announcement shares opened the day at $7.46. The stock continued to rise nearly reaching double Wednesday’s close. While the stock price came back to Earth midday it’s once again on the rise and is  presently trading (2:41 EDT) at $7.42 up $3.31 or 80% on the day.

Not surprisingly, trading volume was through the roof. At the time of this writing, over 20 million shares traded hands today while the average 90-day volume is around 358,000.

Previous article Largest U.S. Refinery Now Belongs To Saudi Arabia
Next article Lets Customers Purchase Products with a Single Touch through Apple Pay
While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. <i>To contact Brendan or give him an exclusive, please contact him at [email protected]</i>

No posts to display